Tracy Setji

Tracy Setji

Auto-generated profile, based on publicly available information

Tracy Setji

Duke University Medical Center, Durham, NC

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2015 in Hospital Practice
Verified
Journal Article
Open access
MMMelanie E. Mabrey
Melanie E. Mabrey
ABAnna Beth Barton
Anna Beth Barton
LCLeonor Corsino
Leonor Corsino
SFSusan B. Freeman
Susan B. Freeman
EDEllen D. Davis
Ellen D. Davis
TSTracy L. Setji
Tracy L. Setji
Evidence of poor outcomes in hospitalized patients with hyperglycemia has led to new and revised guidelines for inpatient management of diabetes. As providers become more aware of the need for better blood glucose control, they are finding limited guidance in the management of patients receiving enteral nutrition. To address the lack of guidelines in this population, Duke University Health System has developed a consistent practice for managing such patients. Here, we present our practice strategies for insulin use in patients receiving enteral nutrition. Essential factors include assessing the patients’ history of diabetes, hyperglycemia, or hypoglycemia and timing and type of feedings. Insulin practices are then designed to address these issues keeping in mind patient safety in the event of abrupt cessation of nutrition. The outcome of the process is a consistent and safe method for glucose control with enteral nutrition.

1 April 2021 in Clinical Diabetes
Verified
Journal Article
Open access
PDF file
TLTara Lenk
Tara Lenk
JWJohn Whittle
John Whittle
SASolomon Aronson
Solomon Aronson
TMTimothy E. Miller
Timothy E. Miller
MFMatthew Fuller
Matthew Fuller
TSTracy Setji
Tracy Setji
Quality Improvement Success Stories are published by the American Diabetes Association in collaboration with the American College of Physicians and the National Diabetes Education Program. This series is intended to highlight best practices and strategies from programs and clinics that have successfully improved the quality of care for people with diabetes or related conditions. Each article in the series is reviewed and follows a standard format developed by the editors of Clinical Diabetes. The following article describes a project at an academic tertiary-care medical center aimed at identifying surgical patients with uncontrolled diabetes early in the preoperative process to improve their perioperative glycemic control and surgical outcomes.

1 May 2013 in Expert Review of Endocrinology & Metabolism
Verified
Journal Article
Closed access
TSTracy Setji
Tracy Setji
MFMark Feinglos
Mark Feinglos
Glucagon-like peptide-1 receptor agonists have become an important therapeutic option for patients with Type 2 diabetes because of their ability to lower blood glucose and help patients lose weight. There are currently three glucagon-like peptide-1 receptor agonists on the market. In the near future, albiglutide will undergo review by the US FDA for possible approval. Results from Phase I/II trials have demonstrated that albiglutide is a safe and efficacious medication for treating Type 2 diabetes. It lowers hemoglobin A1c and decreases bodyweight. It appears to have fewer gastrointestinal side effects than liraglutide. The once-weekly (or possibly longer duration) dosing of albiglutide may improve adherence. Several Phase III trials are expected to be completed in 2013. These trials will shed further light on the safety and efficacy of albiglutide.